Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>= 18 years~* Patients scheduled to undergo hip or knee replacement~* 8 g/dl \< Hb \< 13 g/dl for men and 8 g/dl \< Hb \< 12 g/dl for women at screening (3-4 weeks prior to surgery)~* anemia~* signed written informed consent~Exclusion Criteria:~* immunosuppressive or myelosuppressive therapy~* history of thromboembolic events~* a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient~* hypersensitivity to any component of the formulation~* transfusion within 1 month prior to study inclusion~* liver values 3 times higher than normal~* active severe infection/inflammation~* renal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NaCl 0.9% (Type: PLACEBO_COMPARATOR): None
- Ferinject (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).